Enanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $15.96 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $5.95 on Friday. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.24. The firm’s 50-day moving average is $5.91 and its 200 day moving average is $7.13. The company has a market capitalization of $126.93 million, a PE ratio of -1.20 and a beta of 0.81.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly acquired 45,000 shares of the company’s stock in a transaction dated Wednesday, February 12th. The shares were acquired at an average price of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares of the company’s stock, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 13.89% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.